The conference will bring together industry leaders, academic experts, healthcare stakeholders and governments to make the case for better access to medicines. There will be a wealth of issues to make progress on, including:The new EU Pharmaceutical and Intellectual Property legislation that will shape your future generic and biosimilar development and launch strategies. The opportunities for innovation in value added medicines including repurposing, reformulations and device innovation. The transformative changes to the EU market for medicines such as security of supply and green criteria in procurement and reimbursement policies. The challenges and opportunities for investment in manufacturing and supply chains for greater supply security.
